We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The system, which mirrors a similar EU program, is designed to foster reporting of side effects, which may not have shown up in clinical trials. Read More
Rather than replacing relationships between the FDA’s product centers and patient organizations, the committee aims to expand those connections. Read More